Evaxion Biotech A/S - ADR EVAX

NAS: EVAX | ISIN: US29970R1059 27/06/2025

2,450 USD (-5,22%)

(-5,22%) 27/06/2025

Grafiek Evaxion Biotech A/S - ADR

Grafiek Evaxion Biotech A/S - ADR

1 dag1d -5,22%
1 week1w 0,41%
1 maand1m -0,41%
3 maanden3m 32,43%
6 maanden6m 155,77%
1 jaar1j -14,93%
5 jaar5j -75,23%

Evaxion Biotech A/S - ADR in het nieuws

Toon enkel gratis nieuws

25 juni 2025 · Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus · Persbericht

3 juni 2025 · Evaxion receives grant funding to design new polio vaccine · Persbericht

27 mei 2025 · Evaxion announces business update and first quarter 2025 financial results · Persbericht

23 mei 2025 · Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 · Persbericht

22 mei 2025 · Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 · Persbericht

28 april 2025 · 80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting · Persbericht

10 april 2025 · Evaxion to present at World Vaccine Congress · Persbericht

1 april 2025 · Evaxion announces business update and full year 2024 financial results · Persbericht

27 maart 2025 · Evaxion to announce business update and full year 2024 financial results on April 1, 2025 · Persbericht

25 maart 2025 · Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting · Persbericht

Profiel Evaxion Biotech A/S - ADR

Werknemers: 79

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe